Statistics from Altmetric.com
- CI, confidence interval
- HR, hazard ratio
- MACE, major adverse cardiac events
- MI, myocardial infarction
- PCI, percutaneous coronary intervention
- TVR, target vessel revascularisation
- coronary artery disease
- percutaneous coronary intervention
- HIV infection
- highly active antiretroviral therapy
The advent of new antiretroviral agents in 1996 dramatically reduced human immunodeficiency virus (HIV)-associated morbidity and mortality. Prevention and treatment of cardiovascular complications in HIV infected (HIV+) patients are a new and emerging challenge for physicians caring for these patients because of the prolongation of survival and long term complications of highly active antiretroviral treatment. Few data are available regarding the results of conventional treatment—that is, coronary revascularisation and management of the cardiovascular risk factors in HIV+ patients.1,2 In acute coronary syndromes, previous studies reported a high rate of major adverse cardiac events (MACE) and target vessel revascularisation (TVR) in HIV+ patients.3,4
The objective of this study was to compare the immediate results and long term prognosis after percutaneous coronary intervention (PCI) in HIV+ and non-HIV infected (HIV−) patients.
We conducted an observational study and clinical outcome analysis of 50 consecutive HIV+ patients undergoing PCI (January 2001 to December 2003). All patients underwent PCI during the same admission for ST segment elevation myocardial infarction (MI), non-ST segment elevation MI, unstable angina, and stable angina pectoris. Patients with cardiogenic shock at the time of admission were excluded. A control group of 50 consecutive HIV− patients who underwent PCI, matched for age and sex, were enrolled during the same period. The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the local ethics committee.
Baseline demographic data, cardiovascular risk …